Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours[1] including metastatic breast cancer.[2] It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.[1]

References

  1. ^ a b Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, et al. (November 2014). "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology. 25 (11): 2244–51. doi:10.1093/annonc/mdu390. PMID 25193991.
  2. ^ Clinical trial number NCT02053636 for "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)" at ClinicalTrials.gov
Allikas: http://en.wikipedia.org/wiki/Lucitanib
No tags for this post.